Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical FOV2304 for diabetic macular edema
2010-021291-29Phase 2Completed
- Sponsor
- Fovea Pharmaceuticals
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of safotibant in diabetic macular edema (DME) (3 arms), sponsored by Fovea Pharmaceuticals. Primary endpoint: Change from baseline in central retinal thickness at 12 weeks. Started Dec 2010; status: completed.
02
Drugs
safotibant
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2010-021291-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021291-29.